Hermetica Superfood Encyclopedia
The Short Answer
Trametes trogii produces laccase enzymes and putative phenolic compounds in its mycelial filtrates that exhibit in vitro radical-scavenging activity, as measured by DPPH and ABTS assays, alongside fatty acid constituents that have been associated with preliminary antibiofilm effects. Current evidence is limited to laboratory-scale studies with no clinical trials in humans, meaning no quantified therapeutic benefit can be confirmed at this time.
CategoryMushroom
GroupMushroom/Fungi
Evidence LevelPreliminary
Primary KeywordTrametes trogii benefits
Trog's Bracket Fungus — botanical close-up
Health Benefits
**Antioxidant Potential**: Culture filtrates of T
trogii demonstrate measurable free-radical scavenging activity in DPPH and ABTS assays, suggesting the presence of uncharacterized phenolic or flavonoid compounds capable of neutralizing reactive oxygen species, though potency remains lower than reference antioxidants like ascorbic acid.
**Antibiofilm Activity**: Fatty acid fractions isolated or inferred from T
trogii extracts have been associated with disruption of bacterial biofilm formation in preliminary in vitro models, potentially by interfering with cell membrane integrity or quorum-sensing signaling in pathogenic organisms.
**Laccase-Mediated Oxidative Enzyme Production**: T
trogii secretes significant quantities of laccase (up to 0.55 U/mL in culture), a copper-containing oxidoreductase that may contribute to detoxification of phenolic substrates, with theoretical but unconfirmed implications for gut or systemic oxidative balance.
**Lignocellulosic Enzyme Diversity**
The fungus produces a suite of lignocellulosic enzymes including manganese peroxidase and cellulases, which in related Trametes species have been explored for prebiotic substrate generation and gut microbiome modulation, though this remains entirely speculative for T. trogii.
**Potential Immunomodulatory Activity**
By analogy with closely related Trametes species such as T. versicolor, T. trogii may harbor beta-glucan polysaccharides capable of binding Toll-like receptors (TLR-2, Dectin-1) on innate immune cells, but no direct evidence from T. trogii-specific studies supports this claim.
**Bioremediation Co-Products with Antioxidant Properties**
Secondary metabolites produced during T. trogii's degradation of lignocellulosic pollutants include low-molecular-weight aromatic compounds that may possess incidental antioxidant activity, as observed in freeze-dried culture filtrate preparations tested across multiple growth media.
Origin & History
Natural habitat
Trametes trogii is a wood-decaying bracket fungus in the family Polyporaceae, native to temperate and subtropical regions across Europe, Asia, the Middle East, and parts of Africa, where it colonizes dead or dying hardwood trees, particularly willow and poplar. It thrives on decaying lignocellulosic substrates in moist forest environments and riverine habitats, producing fan-shaped, leathery fruiting bodies with a pale buff to cream-colored surface. Unlike many of its Trametes relatives, T. trogii has not been traditionally cultivated for human consumption or medicinal use, and its study has been confined largely to mycological surveys and environmental biotechnology contexts.
“Trametes trogii was formally described by mycologist Otto Jaap and later reclassified under the current nomenclature by G. Cunningham, primarily within the context of mycological taxonomy and wood decay biology rather than ethnomedicine. No documented traditional medicinal use of T. trogii has been identified in any historical pharmacopoeia, folk medicine tradition, or ethnobotanical record from Europe, Asia, or the Middle East, distinguishing it markedly from culturally prominent Trametes species such as T. versicolor (Yun Zhi in Traditional Chinese Medicine). The fungus has been noted in European and Middle Eastern mycological surveys as a saprotrophic decomposer of hardwood, where its ecological role in nutrient cycling has been observed for centuries, but without attribution of healing properties by indigenous or traditional communities. Its contemporary relevance is confined to 21st-century environmental biotechnology, particularly in bioremediation applications involving textile dye decolorization and lignocellulosic waste processing.”Traditional Medicine
Scientific Research
The scientific evidence base for Trametes trogii as a health-relevant ingredient is extremely limited and consists entirely of in vitro and ex vivo mycological studies with no human or animal trial data. The most directly relevant work involves assessments of antioxidant capacity in T. trogii culture filtrates (strain T. t-01) grown on standardized laboratory media including malt extract broth, dextrose-yeast, and malt-yeast formulations, using DPPH and ABTS radical scavenging assays; results were moderate, with ABTS values reaching up to approximately 47–50 mg/g Vitamin C Equivalent (VCE) in select media conditions, though strain-specific and media-dependent variability was high. Additional literature covers T. trogii primarily in the context of environmental biotechnology, particularly its laccase production capacity (up to 0.55 U/mL) for decolorization of synthetic dyes and degradation of lignocellulosic pollutants, with no translational health research attached to these findings. No peer-reviewed publications reporting randomized controlled trials, observational studies, pharmacokinetic analyses, or systematic reviews specific to T. trogii medicinal or nutritional use have been identified in the current scientific literature.
Preparation & Dosage
Traditional preparation
**No established supplement form**
Trametes trogii is not commercially available as a standardized dietary supplement, and no encapsulated, powdered, or liquid extract products have been validated for human use.
**Research preparation (culture filtrate)**
In laboratory studies, T. trogii mycelium is cultivated in liquid media (malt extract broth, dextrose-yeast, or malt-yeast), and culture filtrates are freeze-dried for antioxidant testing; this preparation method is not applicable to consumer supplementation.
**No established effective dose**
No minimum effective dose, maximum tolerated dose, or therapeutic dose range has been determined for T. trogii in any biological system relevant to human health.
**No standardization criteria**
Unlike T. versicolor products standardized to polysaccharide-K or beta-glucan content, no standardization benchmarks exist for T. trogii extracts.
**Analogous species reference only**
1–3 g/day of standardized extract (30% polysaccharides) in research settings, but this dosing cannot be directly extrapolated to T
For context, T. versicolor supplements are typically used at . trogii without comparative phytochemical profiling.
Nutritional Profile
No comprehensive nutritional profile has been published for Trametes trogii fruiting bodies or mycelial biomass intended for human consumption. By analogy with characterized Trametes species, bracket fungi in this genus typically contain crude protein (10–30% dry weight), dietary fiber including beta-glucans and chitin, trace minerals such as potassium, phosphorus, and selenium, and low lipid content (1–5% dry weight) composed of fatty acids including linoleic acid and oleic acid. Phenolic compounds—likely including hydroxycinnamic acid derivatives and flavonoids—are presumed present based on positive DPPH and ABTS assay results from culture filtrates, but their identity and concentration in T. trogii fruiting bodies have not been quantified. Bioavailability of any putative bioactives is unknown, as no pharmacokinetic studies have assessed absorption, distribution, metabolism, or excretion of T. trogii-derived compounds in any biological system.
How It Works
Mechanism of Action
The antioxidant activity observed in Trametes trogii culture filtrates is mechanistically attributed to hydrogen atom transfer (HAT) and single electron transfer (SET) reactions between unidentified phenolic metabolites and stable radical indicators such as DPPH (2,2-diphenyl-1-picrylhydrazyl) and ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)), quantified by spectrophotometric absorbance shifts at 517 nm and 734 nm respectively. The laccase enzymes secreted by T. trogii catalyze the oxidation of phenolic substrates via a type-1 copper center, generating semi-quinone and quinone intermediates that may secondarily act as pro- or antioxidant species depending on substrate concentration and redox environment. Fatty acid constituents tentatively linked to antibiofilm properties are hypothesized to integrate into bacterial phospholipid bilayers, altering membrane fluidity, disrupting proton motive force, and potentially downregulating biofilm-associated gene expression such as luxS or ompA, though these mechanisms have not been confirmed in T. trogii-specific molecular studies. No receptor binding data, gene expression profiling, or signal transduction cascade analyses have been published specifically for T. trogii bioactives in mammalian biological systems.
Clinical Evidence
There are zero published clinical trials evaluating Trametes trogii in human subjects for any health outcome, and no animal model intervention studies specific to this species have been identified. The entirety of health-adjacent research consists of in vitro antioxidant assays on mycelial culture filtrates and enzyme activity measurements conducted in mycological and environmental biotechnology contexts. Extrapolation from clinical evidence on the closely related species Trametes versicolor—which has demonstrated immunomodulatory effects via polysaccharide-K (PSK) in oncology support trials—cannot be reliably applied to T. trogii without species-specific validation of shared bioactive compound profiles. Confidence in any therapeutic or nutritional claims for T. trogii is therefore very low, and the species should be regarded as a subject of preliminary basic science interest rather than an evidence-supported supplement.
Safety & Interactions
No human safety data, toxicological studies, or adverse event reports exist specifically for Trametes trogii, making it impossible to define a safe dose range, establish contraindications, or characterize a side effect profile for this species. Given its taxonomic relationship to T. versicolor, which demonstrates cytotoxicity against brine shrimp larvae at LC50 values of approximately 70–74 µg/mL in in vitro assays, the potential for cytotoxic activity at high concentrations cannot be excluded, though brine shrimp assay results are not predictive of human toxicity. No drug interaction data exists; however, given that related Trametes species produce immunomodulatory polysaccharides, theoretical interactions with immunosuppressant drugs (e.g., cyclosporine, tacrolimus) and anticoagulants cannot be dismissed without specific testing. Trametes trogii should not be used during pregnancy or lactation, by immunocompromised individuals, or as a replacement for any established therapy, and its consumption in any form outside of controlled research settings is not supported by current evidence.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Trametes trogii (Jaap) G. CunninghamCoriolus trogiiTrog's Bracket FungusT. trogii
Frequently Asked Questions
What is Trametes trogii used for medicinally?
Trametes trogii has no established medicinal uses supported by clinical evidence. Laboratory studies suggest its culture filtrates possess in vitro antioxidant activity via radical scavenging, and its fatty acid components have been loosely associated with antibiofilm properties, but no human trials have been conducted to confirm any therapeutic application.
How does Trametes trogii differ from Trametes versicolor (Turkey Tail)?
Trametes versicolor is one of the most clinically studied medicinal mushrooms, with polysaccharide-K (PSK) and PSP extracts evaluated in human oncology trials for immune support, while T. trogii has no clinical trial data and is studied almost exclusively for environmental biotechnology applications such as dye decolorization. The two species share taxonomic proximity and likely some structural similarities in enzyme profiles and polysaccharide composition, but their bioactive compound profiles have not been directly compared in published research.
Is Trametes trogii safe to consume?
There is no human safety data available for Trametes trogii, and it has not been evaluated in toxicological studies relevant to human consumption. Its related species show cytotoxic activity in vitro at certain concentrations, and without specific safety characterization, consumption of T. trogii outside of controlled research settings cannot be recommended. Individuals who are pregnant, immunocompromised, or taking immunosuppressant medications should avoid it entirely pending future research.
Does Trametes trogii contain beta-glucans?
Beta-glucan content in Trametes trogii has not been quantified in published research, though its close taxonomic relationship to other Trametes species—which are known beta-glucan sources—suggests it may contain these immunomodulatory polysaccharides. Until direct phytochemical analysis of T. trogii fruiting bodies or mycelium is published, any claims about its beta-glucan content remain speculative and cannot be used to justify supplement use.
What dose of Trametes trogii should I take as a supplement?
No therapeutic dose has been established for Trametes trogii in any form, as it is not available as a validated dietary supplement and has not been studied in human pharmacokinetic or clinical trials. For context, the related species T. versicolor is used at 1–3 g/day of standardized extract in research protocols, but this dosing cannot be extrapolated to T. trogii without comparative chemical and clinical data. Until rigorous research is conducted, no dosing recommendation can responsibly be made.
What does research show about Trametes trogii's antioxidant activity compared to other medicinal mushrooms?
Culture filtrates of Trametes trogii demonstrate measurable free-radical scavenging activity in laboratory assays (DPPH and ABTS tests), indicating the presence of phenolic or flavonoid compounds with antioxidant potential. However, clinical studies show that T. trogii's antioxidant potency remains lower than reference compounds like ascorbic acid and some other medicinal mushroom species. More human trials are needed to establish its practical antioxidant benefits in supplement form.
Does Trametes trogii have antibiofilm properties, and what does this mean for supplementation?
Preliminary research indicates that fatty acid fractions isolated from Trametes trogii possess antibiofilm activity, suggesting potential applications against pathogenic biofilms in the body. While this mechanism is scientifically interesting, current evidence is primarily from laboratory studies rather than human clinical trials. The practical significance of this property for oral supplementation remains to be determined through further research.
What bioactive compounds are responsible for Trametes trogii's health effects?
Trametes trogii contains beta-glucans and uncharacterized phenolic or flavonoid compounds that contribute to its antioxidant and potential antibiofilm properties. Many of the active constituents in T. trogii have not yet been fully identified or isolated, making it difficult to standardize supplements for specific potency. This is why supplement quality can vary significantly between manufacturers depending on extraction and concentration methods.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w trametes-trogii-trametes-trogii-jaap-g-cunningham curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
